semaglutide cardiovascular trial news risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 Cardiovascular benefits of semaglutide: a

The study cohort was derived from the PRECARE2 study, an observational, real-world study aimed at evaluating the efficacies of clinical therapeutics on T2D patients

In this diary, write down what you eat, when you take your medication, and when you feel bloated

In the STRIDE trial, once-weekly subcutaneous dosing of semaglutide significantly improved walking capacity and quality of life in patients with T2DM and symptomatic peripheral artery disease (PAD)

Oral Wegovy (Semaglutide Pill) One of the latest advancements in weight management is Oral Wegovy, an FDA-approved semaglutide pill available since December 2025

In 2023, 13.5 % of U.S